Low-Dose Danazol for the Treatment of Telomere Related Diseases
NCT03312400
Recruiting
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA. Some people with short telomeres or other gene changes can develop diseases of the bone marrow, lung, and liver. Researchers want to see if low doses of the hormone drug danazol can help. Objective: To study the safety and effect of low dose danazol. Eligibility: People ages 3 and older with a telomere disease who have either very short te... Read More
Gender:
ALL
Ages:
Between 3 years and 99 years
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Telomere Disease
Register for Updates
Stone and Laser Therapies Post-Market Study (SALT)
NCT06982235
Recruiting
The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and/or therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.
Gender:
ALL
Ages:
All
Trial Updated:
08/21/2025
Locations: University of Miami Hospital, Miami, Florida
Conditions: Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Register for Updates
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820
Recruiting
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: University of California, Los Angeles, Santa Monica, California +13 locations
Conditions: Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
Register for Updates
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618
Recruiting
The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children and adolescents (6 to \<18 Years Old) with moderate atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/21/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +94 locations
Conditions: Atopic Dermatitis
Register for Updates
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
NCT01568697
Recruiting
Background: - Gum disease is a condition in which the tissue around the tooth root becomes swollen and infected. This condition can cause tooth loss if it is not treated. Who gets gum disease and how bad it will be depends on (1) the different bacteria in the mouth and (2) how the immune system of an individual handles these bacteria. Researchers want to look at the oral bacteria and genetic immune problems of different people to learn how these affect gum disease and other conditions of the mo... Read More
Gender:
ALL
Ages:
Between 7 years and 100 years
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immunosuppression, Periodontal Disease, Healthy Subjects, Healthy Volunteer
Register for Updates
Asciminib Roll-over Study
NCT04877522
Recruiting
This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/21/2025
Locations: Michigan Med University of Michigan, Ann Arbor, Michigan +82 locations
Conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Register for Updates
A Study to Assess the Relative Bioavailability of Oral ABBV-932 in Healthy Adult Participants
NCT06849791
Recruiting
This study will assess the relative bioavailability and effect of food on pharmacokinetics of ABBV-932 oral administration in healthy adult participants.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Acpru /Id# 266649, Grayslake, Illinois
Conditions: Healthy Volunteer
Register for Updates
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
NCT04322383
Recruiting
Background: Most people with hairy cell leukemia have a BRAF gene mutation. They can be treated with BRAF inhibitors, drugs that target this mutation. For people who do not have this mutation, BRAF inhibitors are not a treatment option. We found that in hairy cell leukemia, when BRAF is not mutated, the MEK gene frequently is. Binimetinib is a MEK inhibitor which targets MEK. It is important to determine if this drug can be a good treatment option in those who cannot benefit treatment with BRAF... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Hairy Cell Leukemia
Register for Updates
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494
Recruiting
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD. The goals of the study are to learn: * If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein tha... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
08/21/2025
Locations: JEM Research Institute ( Site 1046), Atlantis, Florida +2 locations
Conditions: Early Alzheimer's Disease
Register for Updates
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
NCT05050136
Recruiting
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Southern California Research Center, Coronado, California +100 locations
Conditions: Primary Biliary Cholangitis, PBC
Register for Updates
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
NCT05580458
Recruiting
Background: Shingles is a painful, blistering rash caused by the same virus that causes chickenpox. Shingrix is a vaccine approved to prevent shingles in healthy adults over age 50 and in immunocompromised adults over age 18. Researchers want to learn more about how people with HIV respond to Shingrix. Objective: To learn how Shingrix affects the immune response in people with HIV. Eligibility: People aged 18 years and older with HIV. Healthy people aged 50 years or older are also needed.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Herpes Zoster
Register for Updates
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
NCT07075640
Recruiting
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/21/2025
Locations: Fortrea Clinical Research Unit Inc., Madison, Wisconsin
Conditions: Healthy Participants
Register for Updates